Skip to main content

Search

Search the site:

News, Views, and Advocacy From the Oncology Nursing Society

News & Views

Advocacy

Stories

News & Views

Latest Articles
Clinical Practice
ONS News
ONS Leadership

Trending Topics

Treatments
Research
Safety
COVID-19
Drug Reference Sheet
Clinical practice

View All Topics

Advocacy

Latest Articles
Updates
Get Involved

Stories View All

View All

What It’s Like to Compete in the ONS Hackathon™

Oncology nurse pride

What It’s Like to Compete in the ONS Hackathon™

September 17, 2021

The Case of the Swift Sepsis Response

Oncologic emergencies

The Case of the Swift Sepsis Response

September 03, 2021

The Case of the GVHD Double-Take

Treatment side effects

The Case of the GVHD Double-Take

August 24, 2021

Nurses, Researchers Create Innovative Solutions to Ambulatory Care Challenges in ONS Hackathon

Oncology nurse pride

Nurses, Researchers Create Innovative Solutions to Ambulatory Care Challenges in ONS Hackathon

August 06, 2021

Having a Mentor Helps You Achieve Oncology Nursing Certification

nursing professional development

Having a Mentor Helps You Achieve Oncology Nursing Certification

Search

News & Views

Advocacy

Stories

Home

Author Content

Antibiotics May Reduce Checkpoint Inhibitor Efficacy

Using antibiotics during treatment with immune checkpoint inhibitors may limit the therapy’s effect, according to study results published in the American Journal of Clinical Oncology.

September 22, 2021

Cancer research

This Is Why Red Meat Increases Colorectal Cancer Risk

Frequent red and processed meat consumption leaves a specific pattern of DNA damage in colorectal cells that contributes to the formation of tumors, researchers reported in study findings published in Cancer Discovery.

September 15, 2021

Cancer research

A Body of Evidence Helps Nurses Manage CAR T-Cell Therapy Toxicities

When chimeric antigen receptor (CAR) T-cell therapies were first approved for cancer in 2017, nurses didn’t have years of clinical practice experience with the treatment to understand its full scope of nursing implications yet. Now that nearly five years have passed—and new CAR T-cell therapies have been approved, bringing the total number of treatments to five as well—oncology nurses and nurse scientists have built a robust knowledge base.

September 14, 2021

Prognostic Biomarkers May Help Predict Rhabdomyosarcoma Outcomes

TP53 and MYOD1 variants are associated with more aggressive forms of rhabdomyosarcoma, a rare childhood cancer, and poorer outcomes, according to the results of the largest international genomic profiling study of the disease. The findings, which were published in the Journal of Clinical Oncology, have implications for somatic biomarker testing to guide tailored treatment approaches.

September 09, 2021

BTK Inhibitor Effective for Relapsed Hairy Cell Leukemia

Ibrutinib produces durable disease control for patients with high-risk hairy cell leukemia, a rare cancer, who have relapsed and for whom standard purine analogues are not a feasible therapeutic option, according to study results published in Blood.

September 08, 2021

Cancer research

Testicular Cancer Treatment and Survival Rates Are Improving

Progression-free and overall survival rates for patients with metastatic testicular cancer have significantly grown since 1990, researchers reported in the Journal of Clinical Oncology.

August 25, 2021

Genetics & genomics

Whole-Genome Sequencing May Guide Treatment Choices for AML and MDS

When compared to conventional testing on the same samples from patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), whole-genome sequencing–based testing detected the same abnormalities—and new genetic information in about a quarter of patients, potentially changing treatment selection for more than half of those patients, researchers said in the New England Journal of Medicine.

August 18, 2021

Cancer research

Researchers Tie More Cancers, Mortality to NF1 Disorders

The genetic disorder neurofibromatosis type 1 (NF1) is linked to the development of and mortality for more types of cancer than previously identified, researchers reported in results from a new study. They published the findings in JAMA Network Open.

August 11, 2021

Oncology nurse influence

Coaching Roles Give Nurses New Avenues to Provide Patient-Centered Care

Nurses don’t always have to venture beyond the bedside for unique career change opportunities. Always innovating and evolving, the profession identifies new roles for clinical practice nurses to meet patients’ needs.

August 10, 2021

Heart Failure May Increase Risk for Certain Cancers

Patients with heart failure have a 75% increased risk of developing cancer, researchers reported in ESC Heart Failure. And cancer incidence rates were even higher for specific disease sites.

August 04, 2021

New Form of CAR T Cells May Target Genetic Alteration Common to All Cancers

Scientists created a new cancer immunotherapy approach that uses a new type of CAR T cells to stimulate an immune response against cells that are missing one gene copy. They reported their findings in Proceedings of the National Academy of Sciences.

Cancer research

Scientists Identify Protein Implicated in Tumor Growth, Treatment Resistance

A protein called AMBRA1 may be to blame for tumor resistance to CDK4/6 inhibitors, according to results from international teams of researchers that were reported in Nature.

Long-Term irAEs From Checkpoint Inhibitors Have Considerations for Survivorship

More than 40% of patients with melanoma treated with nivolumab or pembrolizumab experience persistent long-term immune-related adverse events (irAEs) for at least 1.5 years, researchers reported in JAMA Oncology.

The Evidence Is Building for ACE Inhibitors in Anthracycline-Associated Cardiotoxicity

Cardiac toxicities are associated with many types of cancer therapies, with both length of and time since treatment increasing a patient’s risk for the adverse event. Anthracycline chemotherapies are among the oldest agents still used for a variety of cancer diagnoses, and as cancer survivorship continues to grow, more patients are presenting with late-onset cardiac complications.

Clinical practice

Standard Minimum Nurse-to-Patient Ratio Improves Outcomes

Implementing a standard minimum nurse-to-patient ratio lowers mortality, readmission, and length of stay rates, according to findings published in Lancet.

Immunotherapy Extends Survival in Uveal Melanoma

Patients with uveal melanoma who were treated with tebentafusp, an investigational immunotherapy, lived a median 5.7 months longer than those in comparison groups, researchers reported in study findings presented at the American Association for Cancer Research 2021 annual meeting.

Cancer research

Single-Chain Diabodies May Target Variants in Both Solid and Liquid Tumors

Lab-developed antibodies using a single-chain diabody format can target TP53 or RAS variants in solid tumors and T-cell receptor variants in blood cancers, researchers reported in study findings published in Science, Science Immunology, and Science Translational Medicine, respectively.

Racial Minorities Receive More Aggressive EOL Ovarian Cancer Care

During the last month of life, non-White patients are more likely to receive aggressive care with little to no focus on palliative or end-of-life (EOL) care for their ovarian cancer, researchers reported in Cancer.

Managing COVID-19 and Cancer Requires Enhanced Palliative Care Skills

Introducing palliative care from the moment of diagnosis is an essential component of comprehensive care, but it becomes even more critical when patients contract the COVID-19 coronavirus during treatment.

Multimethod Approach Supports Providers’ Mental Health During COVID-19

Providing variety of methods and approaches allows healthcare workers to choose the best options for them to mitigate and treat psychological distress from the COVID-19 coronavirus pandemic, researchers said in a preliminary report published in the Joint Commission Journal on Quality and Patient Safety.

Imaging Test Identifies Treatment Choices for ER-Positive Breast Cancer

Using positron-emission tomography with a radioactive tracer identifies levels of progesterone receptor in patients with estrogen receptor-positive breast cancer, researchers reported in Nature Communications. The diagnostic tool would help clinicians determine which patients are most likely to respond to hormone therapies for breast cancer.

Cancer screening

Survey Results Support Predicted Effects of Pandemic Screening Drop

Clinicians are already seeing an increase in late-stage cancer diagnoses that they attribute to the pandemic-driven pause in cancer screening and treatment adherence, according to the results of a survey from the American Society for Radiation Oncology.

Text Messaging Reduces Disparities in Colorectal Cancer Screening

A series of text reminders to complete an at-home fecal immunochemical test increased screening completion rates by nearly 20%, researchers reported in study findings published in the Journal of General Internal Medicine. The results are particularly encouraging because almost 90% of the participants were Black, a population that typically has low screening adherence rates but higher incidence of and mortality from colorectal cancer.

Targeted Therapy Drug Shows Promise in CLL

Pirtobrutinib, an investigational, third-generation Bruton tyrosine kinase (BTK) inhibitor, offered response rates of 60% or higher in most groups of heavily pretreated patients with chronic lymphocytic leukemia (CLL), even those who’ve received other BTK inhibitors as previous treatment, researchers reported in Lancet.

Targeted therapy

Larotrectinib and Other Tumor-Agnostic Targeted Therapies Are Leading Cancer Care Into the Next Frontier

In 2018, the cancer drug larotrectinib quietly became a milestone along the evolving path to approaching cancer therapy: it was the first agent approved to treat a genetic variant, not a specific type of cancer or disease site. And as oncology treatment science progresses, many predict that it won’t be the last—it’s already been joined by pembrolizumab and entrectinib as tumor-agnostic therapies. The key to curing cancer may be hidden in the disease’s genetic code rather than its location in the body.

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

To discuss the information in this article with other oncology nurses, visit the ONS Communities.

To report a content error, inaccuracy, or typo, email pubONSVoice@ons.org.

content['#byline_profile'].image_alt_text

Elisa Becze BA, ELS, Editor

News, Views, and Advocacy From the Oncology Nursing Society

Legal Notices

Contact Us

Conferences

Advertising

Newsroom

Sitemap

Oncology Nursing Foundation

© Copyright 2021 Oncology Nursing Society

Back to Top ▲